IQVIA Holdings Inc. (NYSE:IQV) Receives $255.82 Average Target Price from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has earned an average rating of “Moderate Buy” from the twenty-one ratings firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $255.82.

Several research firms recently weighed in on IQV. Stephens assumed coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. The Goldman Sachs Group cut their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company.

IQVIA Stock Up 1.2 %

Shares of IQV opened at $197.39 on Wednesday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market cap of $35.83 billion, a P/E ratio of 25.90, a price-to-earnings-growth ratio of 2.05 and a beta of 1.49. The company’s 50-day moving average price is $202.86 and its 200 day moving average price is $222.07. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73.

Institutional Investors Weigh In On IQVIA

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Canada Pension Plan Investment Board grew its position in shares of IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after acquiring an additional 211,653 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after purchasing an additional 86,870 shares during the period. FMR LLC increased its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Finally, Impax Asset Management Group plc lifted its position in shares of IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after buying an additional 157,809 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.